Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model

Thrombosis Research

Volumn 107, Issue 1-2, 2002, Pages 39-43

  Schlitt, A ^a   Hauroeder, B ^b   Buerke, M ^a   Peetz, D ^a   Victor, A ^a   Hundt, F ^c   Bickel, C ^b   Meyer, J ^a   Rupprecht, H J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

^c Division Henning   (Germany)

Author keywords

Aspirin; Clopidogrel; Flow chamber; Heart valve thrombosis; Mechanical heart valves; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN; DRUG DERIVATIVE; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLOOD FLOW; CAROTID ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; ELECTRON MICROSCOPY; ERYTHROCYTE; HEART VALVE PROSTHESIS; JUGULAR VEIN; LAMINAR FLOW; MALE; NONHUMAN; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RABBIT; THROMBOCYTE; THROMBOGENESIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; ANIMAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG SCREENING; IN VITRO STUDY; PATHOLOGY; THROMBOSIS;

ANIMALS; ASPIRIN; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HEART VALVE PROSTHESIS; MALE; MICROSCOPY, ELECTRON; RABBITS; THROMBOSIS; TICLOPIDINE; WARFARIN;

EID: 0037101593     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00185-8     Document Type: Article

References (13)

1. Cannegieter S.C., Torn M., Rosendaal F.R. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J. Intern. Med. 245(4):Apr. 1999;369-374. [Review].
2. Palareti G., Hirsh J., Legnani C., Manotti C., D'Angelo A., Pengo V.et al. Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch. Intern. Med. 160(4):2000;470-478.
3. Hsin M., Speight J., Cooper G.J. Anticoagulant control in the first three months after mechanical heart valve replacement. Int. J. Clin. Pract. 51(7):1997;427-429.
4. Huber K.C., Gersh B.J., Bailey K.R., Schaff H.V., Hodge D.O., Cha R.H.et al. Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement: a 23-year population-based study. Mayo Clin. Proc. 72(12):1997;1103-1110.
5. Schühlen H., Hadamitzky M., Walter H., Ulm K., Schömig A. Major benefits from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement. Circulation. 95(8):1997;2015-2021.
6. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelson H., Fontanelli A.et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. Circulation. 98:1998;2126-2132.
7. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH,Investigators ft. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 8;102(6):624-9
8. Herbert J.M., Dol F., Bernat A., Falotico R., Lale A., Savi P. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb. Haemost. 80:1998;512-518.
9. Badimon L., Turito V., Rosemark J.A., Badimon J.J., Fustrer V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J. Lab. Clin. Med. 110(6):Dec. 1987;706-718.
10. Shea S.M., Karnovsky M.J., Bossert W.H. Vesicular transport across endothelium: simulation of a diffusion model. J. Theor. Biol. 24(1):Jul. 1969;30-42.
11. Czer L.S.C., Matloff J.M., Chaux A., DeRobertis R.N., Gray R.J. Comparative clinical experience with porcine bioprosthetic and St. Jude valve replacement. Chest. 91(4):1987;503-514.
12. Ribeiro P.A., Al Zaibag M., Idris M., Al Kasab S., Davies G., Mashat E.et al. Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude medical aortic prosthesis in patients with rheumatic heart disease. J. Thorac. Cardiovasc. Surg. 91:1986;92-98.
13. Aramendi J.L., Agredo J., Llorente A., Larrarte C., Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J. Heart Valve Dis. 7(6):1998;610-614.